which allows for a once-weekly injection administered by a healthcare professional that takes between 30 and 90 seconds, rather than a weekly, hour-long IV infusion delivered at a clinic with Vyvgart.

The company's lead product, VYVGART (efgartigimod), has shown impressive performance in treating myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP), positioning argenx ...

The company's lead product, VYVGART (efgartigimod), has shown impressive performance in treating myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP), positioning ...

The company’s lead product, VYVGART (efgartigimod), has shown impressive performance in treating myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP), positioning argenx ...

The subcutaneously-administered drug is an FcRn-targeting antibody that will compete with Argenx’s intravenous Vyvgart (efgartigimod ... hour-long IV infusion delivered at a clinic.

Efgartigimod alfa-fcab (Vyvgart) is a human IgG1 antibody fragment. It is formulated as concentrated solution for infusion for intravenous and solution for subcutaneous route of administration.

Efgartigimod alfa-fcab (Vyvgart) is a human IgG1 antibody fragment. It is formulated as concentrated solution for infusion for intravenous and solution for subcutaneous route of administration.